



# FEP Medical Policy Manual

## FEP 7.01.126 Image-Guided Minimally Invasive Decompression for Spinal Stenosis

Annual Effective Policy Date: July 1, 2026

Original Policy Date: June 2012

Related Policies:

7.01.107 - Interspinous and Interlaminar Stabilization/Distraction Devices (Spacers)

Image-Guided Minimally Invasive Decompression for Spinal Stenosis

Description

### Description

Image-guided minimally invasive decompression describes a percutaneous procedure for decompression of the central spinal canal in individuals with spinal stenosis and hypertrophy of the ligamentum flavum. In this procedure, a specialized cannula and surgical tools (mild) are used under fluoroscopic guidance for bone and tissue sculpting near the spinal canal. Image-guided minimally invasive lumbar decompression is proposed as an alternative to existing posterior decompression procedures.

### OBJECTIVE

The objective of this evidence review is to determine whether image-guided minimally invasive lumbar decompression improves the net health outcome in individuals with spinal stenosis.

### POLICY STATEMENT

Image-guided minimally invasive spinal decompression is considered **investigational**.

## POLICY GUIDELINES

None

## BENEFIT APPLICATION

Experimental or investigational procedures, treatments, drugs, or devices are not covered (See General Exclusion Section of brochure).

## FDA REGULATORY STATUS

In 2006, the X-Sten MILD Tool Kit (now the mild device kit, X-Sten Corp. renamed Vertos Medical) was cleared for marketing by the U.S. Food and Drug Administration through the 510(k) process for treatment of various spinal conditions. This set of specialized surgical instruments is used to perform percutaneous lumbar decompressive procedures.

Vertos's mild instructions state that the device is not intended for disc procedures but rather for tissue resection at the perilaminar space, within the interlaminar space, and at the ventral aspect of the lamina. The device is not intended for use near the lateral neural elements and remains dorsal to the dura using image guidance and anatomic landmarks.

Food and Drug Administration product code: HRX.

## RATIONALE

### Summary of Evidence

For individuals who have lumbar spinal stenosis who receive image-guided minimally invasive lumbar decompression (MILD), the evidence includes a large, randomized controlled trial (RCT) (N=302), a second RCT (N=138) comparing MILD to non-surgical conventional medical management (CMM), a systematic review that included a small RCT (N=38), and a number of prospective and retrospective cohort studies and case series. Relevant outcomes are symptoms, functional outcomes, health status measures, and treatment-related morbidity. The largest RCT (MIDAS Encore) compared image-guided MILD with epidural steroid injections (control) in patients who had ligamentum flavum hypertrophy and who failed conservative therapy. Results suggested reductions in pain and improvements in function scores in the image-guided MILD group versus the control group. The trial was unblinded, and there is evidence of differing expectations and follow-up in the 2 groups, suggesting a high risk of bias. The MOTION RCT compared MILD as first-line therapy in combination with nonsurgical CMM to CMM alone in 138 individuals with lumbar spinal stenosis. At 1-year follow-up, patients in the MILD + CMM group experienced a 16.1-point composite Oswestry Disability Index (ODI) mean improvement (the primary outcome), compared with a 2.0-point mean improvement for participants in the CMM-alone arm (p<.001). A major limitation of this trial was the wide variation in CMM interventions received by individuals in both the intervention and control groups; for example, 38.7% of individuals in the CMM alone group received no interventional therapy. Lack of blinding and follow-up for only 12 months were additional limitations. The available evidence is insufficient to determine the efficacy of MILD compared with placebo, open decompression, or conservative treatment. Well-designed and conducted trials with relevant control groups could provide greater certainty on the risks and benefits of this procedure. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have cervical or thoracic spinal stenosis who receive image-guided minimally invasive spinal decompression, no evidence was identified. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

## SUPPLEMENTAL INFORMATION

### Practice Guidelines and Position Statements

Guidelines or position statements will be considered for inclusion in 'Supplemental Information' if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

## Lumbar Spinal Stenosis Consensus Group

In 2018, the Lumbar Spinal Stenosis Consensus Group, composed of a panel of nationally recognized spine experts, convened to evaluate the available literature and develop guidelines for minimally invasive spine treatment (MIST Guidelines).<sup>14</sup> Based on a systematic review of the available literature on percutaneous image-guided lumbar decompression, the consensus committee determined there is sufficient support to warrant Level I evidence (Grade A, Level I, Consensus strong). Grade A evidence is defined as "extremely recommendable (good evidence that the measure is effective and that benefits outweigh the harms)."

## North American Spine Society

In 2011, the North American Spine Society revised clinical practice guidelines on the diagnosis and treatment of degenerative lumbar spinal stenosis.<sup>15</sup> Treatment recommendations included:

- Interlaminar epidural steroid injection for short-term ( 6 weeks to 6 months) symptom relief in patients with neurogenic claudication or radiculopathy; however, there is conflicting evidence regarding long-term efficacy. (Grade of Recommendation: B)
- A multiple injection regimen of radiographically-guided transforaminal epidural steroid injection or caudal injection for medium-term relief of pain. (Grade of Recommendation: C)
- Decompressive surgery to improve outcomes in patients with moderate to severe symptoms of lumbar spinal stenosis. (Grade of Recommendation: B)

No specific recommendations on percutaneous image-guided lumbar decompression were provided.

## U.S. Preventive Services Task Force Recommendations

Not applicable.

## Medicare National Coverage

The Centers for Medicare & Medicaid Services determined that percutaneous image-guided lumbar decompression would be covered by Medicare when provided in a clinical study through coverage with evidence development for beneficiaries with lumbar spinal stenosis enrolled in an approved clinical study meeting criteria in the decision memo (NCD 150.13).<sup>16</sup> According to the national coverage decision, percutaneous image-guided lumbar decompression is a posterior decompression of the lumbar spine performed under indirect image guidance without any direct visualization of the surgical area. This procedure is proposed as a treatment for symptomatic lumbar spinal stenosis unresponsive to conservative therapy. This procedure is generally described as a noninvasive procedure using specially designed instruments to percutaneously remove a portion of the lamina and debulk the ligamentum flavum. The procedure is performed under x-ray guidance (eg, fluoroscopic, computed tomography) with contrast media to identify and monitor the compressed area via epidurogram.

## REFERENCES

1. Chou R, Baisden J, Carragee EJ, et al. Surgery for low back pain: a review of the evidence for an American Pain Society Clinical Practice Guideline. *Spine (Phila Pa 1976)*. May 01 2009; 34(10): 1094-109. PMID 19363455
2. Chou R, Loeser JD, Owens DK, et al. Interventional therapies, surgery, and interdisciplinary rehabilitation for low back pain: an evidence-based clinical practice guideline from the American Pain Society. *Spine (Phila Pa 1976)*. May 01 2009; 34(10): 1066-77. PMID 19363457
3. Weinstein JN, Lurie JD, Tosteson TD, et al. Surgical versus nonsurgical treatment for lumbar degenerative spondylolisthesis. *N Engl J Med*. May 31 2007; 356(22): 2257-70. PMID 17538085
4. Weinstein JN, Tosteson TD, Lurie JD, et al. Surgical versus nonsurgical therapy for lumbar spinal stenosis. *N Engl J Med*. Feb 21 2008; 358(8): 794-810. PMID 18287602
5. Staats PS, Benyamin RM, McDonnell F, et al. MiDAS ENCORE: Randomized Controlled Clinical Trial Report of 6-Month Results. *Pain Physician*. Feb 2016; 19(2): 25-38. PMID 26815247
6. Benyamin RM, Staats PS, MiDAS Encore I. MILD Is an Effective Treatment for Lumbar Spinal Stenosis with Neurogenic Claudication: MiDAS ENCORE Randomized Controlled Trial. *Pain Physician*. May 2016; 19(4): 229-42. PMID 27228511
7. Staats PS, Chafin TB, Golovac S, et al. Long-Term Safety and Efficacy of Minimally Invasive Lumbar Decompression Procedure for the Treatment of Lumbar Spinal Stenosis With Neurogenic Claudication: 2-Year Results of MiDAS ENCORE. *Reg Anesth Pain Med*. Oct 2018; 43(7): 789-794. PMID 30199512

8. Deer TR, Costandi SJ, Washabaugh E, et al. The MOTION Study: A Randomized Controlled Trial with Objective Real-World Outcomes for Lumbar Spinal Stenosis Patients Treated with the mild Procedure: One-Year Results. Pain Med. Apr 08 2022; 23(4): 625-634. PMID 35167700

9. Deer TR, Chafin TB, Costandi SJ, et al. The MOTION study: Two-year results of a real-world randomized controlled trial of the mild procedure for treatment of lumbar spinal stenosis. Pain Pract. Jan 2024; 24(1): 109-119. PMID 37661347

10. Costandi SJ, Deer TR, Chafin TB, et al. Three-year results of the MOTION randomized controlled trial for treatment of lumbar spinal stenosis using the percutaneous mild Procedure. Interv Pain Med. Mar 2025; 4(1): 100561. PMID 40161895

11. Kreiner DS, MacVicar J, Duszynski B, et al. The mild procedure: a systematic review of the current literature. Pain Med. Feb 2014; 15(2): 196-205. PMID 24308292

12. Brown LL. A double-blind, randomized, prospective study of epidural steroid injection vs. the mild procedure in patients with symptomatic lumbar spinal stenosis. Pain Pract. Jun 2012; 12(5): 333-41. PMID 22272730

13. Chopko BW. Long-term results of percutaneous lumbar decompression for LSS: two-year outcomes. Clin J Pain. Nov 2013; 29(11): 939-43. PMID 23446067

14. Deer TR, Grider JS, Pope JE, et al. The MIST Guidelines: The Lumbar Spinal Stenosis Consensus Group Guidelines for Minimally Invasive Spine Treatment. Pain Pract. Mar 2019; 19(3): 250-274. PMID 30369003

15. North American Spine Society (NASS). Evidence-Based Clinical Guidelines for Multidisciplinary Spine Care: Diagnosis and Treatment of Degenerative Lumbar Spinal Stenosis. 2011; <https://www.spine.org/Portals/0/Assets/Downloads/ResearchClinicalCare/Guidelines/LumbarStenosis.pdf>. Accessed March 9, 2026.

16. Centers for Medicare & Medicaid Services. National Coverage Determination (NCD) for Percutaneous Image-guided Lumbar Decompression for Lumbar Spinal Stenosis (2020) <https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?ncdid=358&ncdver=2>. Accessed March 9, 2026.

**POLICY HISTORY - THIS POLICY WAS APPROVED BY THE FEP® PHARMACY AND MEDICAL POLICY COMMITTEE ACCORDING TO THE HISTORY BELOW:**

| Date           | Action         | Description                                                                                                                                                                                                                                          |
|----------------|----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| December 2011  | New policy     |                                                                                                                                                                                                                                                      |
| June 2013      | Replace policy | Policy updated with literature review, references added, reordered and renumbered. No change in policy statement.                                                                                                                                    |
| September 2014 | Replace policy | Policy updated with literature review; references 5-6 added. Policy statement unchanged.                                                                                                                                                             |
| June 2018      | Replace policy | Policy updated with literature review through February 5, 2018; no references added. Policy statement changed from medically necessary for central stenosis without nerve root compression or disc herniation to investigational for all conditions. |
| June 2019      | Replace policy | Policy updated with literature review through February 19, 2019; no references added. Policy statement unchanged.                                                                                                                                    |
| June 2020      | Replace policy | Policy updated with literature review through January 30, 2020; references added. Policy statement unchanged.                                                                                                                                        |
| June 2021      | Replace policy | Policy updated with literature review through March 7, 2021; no references added. Rationale section revised to add clinical context. Policy statement unchanged.                                                                                     |
| June 2022      | Replace policy | Policy updated with literature review through March 4, 2022; no references added. Policy statement unchanged.                                                                                                                                        |
| June 2023      | Replace policy | Policy updated with literature review through March 6, 2023; reference added. Policy statements unchanged.                                                                                                                                           |
| June 2024      | Replace policy | Policy updated with literature review through March 11, 2024; reference added. Policy statement unchanged.                                                                                                                                           |
| June 2025      | Replace policy | Policy updated with literature review through February 21, 2025; no references added. Policy statement unchanged.                                                                                                                                    |
| June 2026      | Replace policy | Policy updated with literature review through March 9, 2026; reference added. Policy statement unchanged.                                                                                                                                            |

The policies contained in the FEP Medical Policy Manual are developed to assist in administering contractual benefits and do not constitute medical advice. They are not intended to replace or substitute for the independent medical judgment of a practitioner or other health care professional in the treatment of an individual member. The Blue Cross and Blue Shield Association does not intend by the FEP Medical Policy Manual, or by any particular medical policy, to recommend, advocate, encourage or discourage any particular medical technologies. Medical decisions relative to medical technologies are to be made strictly by members/patients in consultation with their health care providers. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that the Blue Cross and Blue Shield Service Benefit Plan covers (or pays for) this service or supply for a particular member.